Results of a 5 year N-of-1 GHRH gene therapy experiment

Rejuvenation Res. 2021 Nov 27. doi: 10.1089/rej.2021.0036. Online ahead of print.ABSTRACTHere presented for the first time, are results showing persistence over a 5+ year period, in a human who had a hormone gene therapy administered to muscle. This GHRH therapy was administered in 2 doses, a year apart, with a mean after the second dose of 195 ng/ml (13X normal, σ=143, σM= 34, max=495, min=53). This level of GHRH therapy appears to be safe for the subject, although there were some adverse events. IGF-1 levels were little affected, nor were GH test results, showing no indications of acromegaly for the hormone homolog used. Heart rate declined 8 to 13 bpm, persistent over 5 years. Testosterone rose by 52% (σ=22%, σM=6%). HDL/LDL ratio dropped from 3.61 to mean 2.81 (σ=0.26, σM=0.057, max=3.3, min=2.5), triglycerides declined from 196 mg/dL to mean 94.4 mg/dL (σ=21.9, σM=5.0, min=59, max=133, min=59). White blood cell counts increased, however the baseline was not strong. CD4 and CD8 mean increased 11.7% (σ=11.6%, σM=3.3%, max=30.7%, min=-9.6%) and 12.0% (σ=10.5%, σM=3.0%, max=29.1%, min=-6.7%) respectively. Ancillary observations comprise an early period of euphoria, and dramatic improvement in visual correction after the first dose, spherical correction from baseline (L/R) -2.25/-2.75 to -0.25/-0.5. Over the next 5 years correction drifted back to -1.25/-1.75. Horvath phenoage was cut 44.1% post-treatment. At completion, epigenetic age was -6 years (-9.3%), and te...
Source: Cell Research - Category: Cytology Authors: Source Type: research